Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Jun 16, 2017
Insider Transaction Report
Form 4
Ruchefsky Steven B
Director
Transactions
- Sale
Common Stock
2017-06-14$89.48/sh−20,000$1,789,574→ 205,426 total
Footnotes (2)
- [F1]The reporting person's sale of the Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,400 shares, with the reporting person's purchase of 1,400 shares of the Issuer's common stock at a price of $69.50 per share on May 9, 2017. The reporting person has agreed to pay to the Issuer, upon settlement of the trade, $28,945 representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.25 to $90.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.